The newly FDA-approved AI-powered software platform BrainSee utilizes brain MRI and cognitive assessments to reportedly predict the progression of amnestic mild cognitive impairment to Alzheimer disease in 5 years.
FDA News
Advertisement
Catch up on any of the neurology news headlines you may have missed over the course of January 2024, compiled all into one place by the NeurologyLive® team.
Advertisement
Months after the FDA cleared a phase 2 study in myasthenia gravis, KYV-101 is set to be assessed in a diverse cohort of refractory progressive multiple sclerosis.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA and EMA Accepts Regulatory Applications for Cemdisiran in Generalized Myasthenia Gravis
2
Linking Plasma p-tau217 to Brain Metabolism in Alzheimer Disease: Insights With Ana C. Pereira, MD
3
Teva Submits NDA for Ecopipam, Potential First New Tourette Syndrome Treatment in Over a Decade
4
Bevacizumab Secures Approval in Japan as World's First Therapy for Neurofibromatosis Type 2
5